Skip to main content

Table 5 Perceived benefits and challenges regarding the current individualized (X) DR TB treatment

From: Acceptability, feasibility, and likelihood of stakeholders implementing the novel BPaL regimen to treat extensively drug-resistant tuberculosis patients

   Indonesia Kyrgyzstan Nigeria
Acceptability Perceived benefits regarding the current ITR • Proven efficacy according to WHO
• Monitoring and management of AEs covered by health insurance
• Enablers and nutrition provided with the regimen
• Reduced side effects of current ITR compared to the one before
• Good completion rates
• No resistance yet
• Use in children possible
• Funding for drugs through the Global Fund
• Monitoring also funded
Perceived challenges regarding the current ITR • Long duration of treatment
• High pill burden
• High health worker and health facility workload
• Side effects common
• Injectables
• Difficulty in quantification and forecasting due to individual dosing • Limited adherence
• Difficulties with treatment monitoring
• Difficulties in allocating treatment in children
• Injectables (resulting in AEs and high HR needs)
• Hospitalization
• High workload on home visits if home-based care setting
• Diagnostic treatment gap due to lack of funding for travel for baseline investigations
• Limited adherence
• Lack of tests for all examinations for AEs
• High cost for monitoring
• Difficulty in quantification and forecasting due to individual dosing
  1. AE adverse event, ITR individualized treatment regimen, HR human resources